司美格鲁肽对肥胖相关HFpEF患者NT-proBNP的影响:STEP-HFpEF项目分析
该研究为STEP-HFpEF和STEP-HFpEF DM两项随机双盲安慰剂对照试验的预设二次分析,共纳入1145例肥胖相关射血分数保留的心力衰竭(HFpEF)患者。结果显示,司美格鲁肽2.4 mg治疗52周可降低NT-proBNP(估计治疗比0.82;95%CI 0.74-0.91;P=0.0002),且基线NT-proBNP较高的患者健康状态改善更明显,而体重下降在各基线NT-proBNP水平间一致。
要点
- 司美格鲁肽2.4 mg治疗52周可降低肥胖相关HFpEF患者的NT-proBNP。
- 基线NT-proBNP较高的患者健康状态改善更显著,存在交互作用。
- 体重下降在各基线NT-proBNP水平间无显著差异。
核心结论
- 在肥胖相关HFpEF患者中,司美格鲁肽降低NT-proBNP,且基线NT-proBNP较高者症状和躯体限制改善更明显。
研究设计与样本
- 预设二次分析,汇总STEP-HFpEF和STEP-HFpEF DM两项双盲、安慰剂对照、随机试验数据,共1145例患者随机。
主要发现
- 司美格鲁肽对比安慰剂52周NT-proBNP估计治疗比为0.82(95%CI 0.74-0.91;P=0.0002)。
- 健康状态改善随基线NT-proBNP三分位升高而增大:三分位1估计差异4.5分(95%CI 0.8-8.2),三分位2为6.2分(95%CI 2.4-10.0),三分位3为11.9分(95%CI 8.1-15.7);交互P=0.02。
- 基线NT-proBNP作为连续变量时交互P=0.004。
- 体重下降在各基线NT-proBNP水平间一致(交互P=0.21)。
临床怎么用
- 对于肥胖相关HFpEF患者,司美格鲁肽可考虑用于降低NT-proBNP并改善症状,尤其基线NT-proBNP较高者可能获益更大。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
BACKGROUND: The glucagon-like peptide-1 receptor agonist, semaglutide, improved health status and reduced body weight in patients with obesity-related heart failure (HF) with preserved ejection fraction (HFpEF) in the STEP-HFpEF (Semaglutide Treatment Effect in People with Obesity and HFpEF) program. Whether benefits were due to mechanical unloading or effects on HF pathobiology is uncertain. OBJECTIVES: This study sought to determine if semaglutide 2.4 mg reduced N-terminal pro-B-type natriuretic peptide (NT-proBNP) in patients with obesity-related HFpEF and compare treatment responses by baseline NT-proBNP. METHODS: This was a prespecified secondary analysis of pooled data from 2 double-blind, placebo-controlled, randomized trials (STEP-HFpEF [Research Study to Investigate How Well Semaglutide Works in People Living With Heart Failure and Obesity] and STEP-HFpEF DM [Research Study to Look at How Well Semaglutide Works in People Living With Heart Failure, Obesity and Type 2 Diabetes]) testing effects of semaglutide in patients with obesity-related HFpEF. The main outcomes were change in NT-proBNP at 52 weeks and change in the dual primary endpoints of Kansas City Cardiomyopathy Questionnaire Clinical Summary Score and body weight by baseline NT-proBNP. RESULTS: In total, 1,145 patients were randomized. Semaglutide compared with placebo reduced NT-proBNP at 52 weeks (estimated treatment ratio: 0.82; 95% CI: 0.74-0.91; P = 0.0002). Improvements in health status were more pronounced in those with higher vs lower baseline NT-proBNP (estimated difference: tertile 1: 4.5 points, 95% CI: 0.8-8.2; tertile 2: 6.2 points, 95% CI: 2.4-10.0; tertile 3: 11.9 points, 95% CI: 8.1-15.7; P interaction = 0.02; baseline NT-proBNP as a continuous variable: P interaction = 0.004). Reductions in body weight were consistent across baseline NT-proBNP levels (P interaction = 0.21). CONCLUSIONS: In patients with obesity-related HFpEF, semaglutide reduced NT-proBNP. Participants with higher baseline NT-proBNP had a similar degree of weight loss but experienced larger reductions in HF-related symptoms and physical limitations with semaglutide than those with lower NT-proBNP.
引用
- Petrie MC, Borlaug BA, Butler J, et al. Semaglutide and NT-proBNP in Obesity-Related HFpEF: Insights From the STEP-HFpEF Program. J Am Coll Cardiol. 2024. PMID: 38819334. doi:10.1016/j.jacc.2024.04.022
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。